Displaying 69 out of 946 Biotech companies
 Filter
City
Country
Stage
Business Model
Industry
company score funding investors employees industries biz model city contact
SynOx Therapeutics HIRING

Developer of treatment for diffuse tenosynovial giant cell tumors.

75
$75M · Series B Bioqube Ventures, Medicxi, Forbion Capital Partners 1 to 10 Health Tech, Biotech B2B Dublin, Ireland •••••••••••@synoxtherapeutics.com
Tubulis

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases.

68
$139M · Series B Nextech Invest, EQT Life Sciences, Andera Partners 11 to 50 Health Tech, Biotech, Deep Tech B2B Munich, Germany •••••••••••@tubulis.com
BioptimusJUST ADDED

Developer of a universal AI foundation model for biology.

68
$35M · Seed Frst, Bpifrance, Sofinnova Partners 1 to 10 AI, Biotech B2B, SaaS Paris, France •••••••••••@bioptimus.com
Flindr TherapeuticsJUST ADDED HIRING

Precision oncology treatments developer.

68
$21M · Series A V-Bio Ventures 1 to 10 Health Tech, Biotech Amsterdam, Netherlands •••••••••••@flindrtx.com
Adionics

Eco-friendly liquid-liquid direct lithium extraction (DLE) process developer.

64
$27M · Series B Celeste Management, Sociedad Quimica Y Minera (SQM), Bpifrance 11 to 50 Climate Tech & Green Tech, Biotech B2B Paris, France •••••••••••@adionics.com
Aqemia

Drug discovery platform.

64
$32M · Series A Wendel Growth, Bpifrance, Elaia 51 to 100 Biotech B2B Paris, France •••••••••••@aqemia.com
Baseimmune

AI vaccine algorithm developer.

64
$11M · Series A Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures 1 to 10 AI, Biotech B2B, SaaS London, UK •••••••••••@baseimmune.co.uk
Causaly

Biomedical research discovery tool.

64
$60M · Series B ICONIQ Growth, Index Ventures, Pentech Ventures 51 to 100 Health Tech, AI, Biotech, Pharma B2B, SaaS London, UK •••••••••••@causaly.com
Beacon Therapeutics

Oophthalmic gene therapy company to treat blinding retinal illnesses.

64
$120M · Series A Syncona Partners LLP 1 to 10 Health Tech, Biotech London, UK •••••••••••@beacontx.com
Apollo Therapeutics

Portfolio of pharmaceutical research and discovery.

64
$33M · Series C Patient Square Capital, Rock Springs Capital, M&G Investments 1 to 10 Biotech, Pharma London, UK •••••••••••@apollotherapeutics.com
Eligo Bioscience

Gene-editing platform.

64
$30M · Series B Sanofi Ventures, Khosla Ventures, Bpifrance 11 to 50 Health Tech, Biotech Paris, France •••••••••••@eligo.bio
MIP DiscoveryJUST ADDED

Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies.

64
$8M · Series A Mercia Asset Management 11 to 50 Health Tech, Biotech London, UK •••••••••••@mipdiscovery.com
Cure51JUST ADDED HIRING

Cancer survivors data analysis platform.

64
$16M · Seed Hitachi Ventures, Life Extension Ventures, Sofinnova Partners 11 to 50 Biotech, Data and Analytics B2B, SaaS Paris, France •••••••••••@cure51.com
Mnemo Therapeutics

Mnemo Therapeutics specializes in biotechnology and life science.

59
$89M · Series A Sofinnova Partners 101 to 250 Health Tech, Biotech B2B Paris, France •••••••••••@mnemo-tx.com
Mytos

Fully-automated cell manufacturing.

59
$19M · Series A Buckley Ventures, Wing Venture Capital, IQ Capital Partners 11 to 50 Biotech, Machine Learning B2B London, UK •••••••••••@mytos.bio
Onego Bio HIRING

Animal-free egg protein producer for food manufacturers.

59
$28M · Series A EIT Food, Agronomics, Tesi 11 to 50 Foodtech, Biotech B2B Helsinki, Finland •••••••••••@onego.bio
Orbis Medicines

Oral macrocycle drug discovery platform.

59
$28M · Seed Novo A/S, Forbion Capital Partners 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@orbismedicines.com
SparingVision

SparingVision is a biotechnology company focused development of genomic medicines for the treatment of blinding inherited retinal diseases.

59
$52M · Series A Ysios Capital 1 to 10 Health Tech, Biotech, Deep Tech B2B Paris, France •••••••••••@sparingvision.com
Complement Therapeutics

Preclinical stage treatment for geographic atrophy.

59
$78M · Series A Forbion Capital Partners, Gimv 1 to 10 Biotech London, UK •••••••••••@complementtx.com
FA Bio

Discovery and development platform of superior microbial bioproducts.

59
$6M · Series A Pymwymic, Clean Growth Fund 1 to 10 Biotech London, UK •••••••••••@fungialert.com
Calluna Pharma

Developer of therapies for inflammatory and fibrotic diseases.

59
$81M · Series A Sarsia, p53, Forbion Capital Partners 11 to 50 Biotech, Pharma Oslo, Norway •••••••••••@callunapharma.com
IMU Biosciences

AI platform to map the human immune system.

59
$14M · Series A Life Extension Ventures, Molten Ventures 11 to 50 Health Tech, Biotech London, UK •••••••••••@imubiosciences.com
Stanhope AIJUST ADDED HIRING

Neuroscience-driven AI platform.

59
$2M · Seed Rockmount Capital, UCL Technology Fund, Moonfire Ventures 11 to 50 AI, Biotech B2B, SaaS London, UK •••••••••••@stanhopeai.com
MetyosJUST ADDED HIRING

Biosensors developer to combat chronic kidney disease.

59
$2M · Pre Seed Bpifrance, Kima Ventures, Cenitz 1 to 10 Health Tech, Biotech Paris, France •••••••••••@metyos.com
SparxellJUST ADDED HIRING

Developer of sustainable plant-based pigments.

59
$3M · Seed PDS Ventures, Circular Innovation Fund, L'Oreal 1 to 10 Biotech, Manufacturing B2C London, UK •••••••••••@sparxell.com
Hexigone InhibitorsJUST ADDED HIRING

Sustainable corrosion inhibitors manufacturer.

59
$1M · Seed Oxford Innovation Finance, Waterspring Ventures, Development Bank of Wales 1 to 10 Biotech, Manufacturing B2B London, UK •••••••••••@hexigone.com
CatalYm

Innovative immunotherapies developer for cancer patients.

54
$51M Forbion Capital Partners, Vesalius Biocapital Partners, Bayern Kapital 11 to 50 Health Tech, Biotech, Manufacturing B2B Munich, Germany •••••••••••@catalym.com
Charm Therapeutics

CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.

54
$50M · Series A General Catalyst, Khosla Ventures 1 to 10 Health Tech, AI, Biotech, Data and Analytics B2B London, UK •••••••••••@charmtx.com
Egle Therapeutics

Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.

54
$46M Bioqube Ventures 11 to 50 Health Tech, Biotech B2B Paris, France •••••••••••@egle-tx.com
Eyevensys

Eyevensys creates ophthalmic therapeutic bio factories to sustainably treat major eye diseases.

54
$30M · Series B Pureos Bioventures, Karista 11 to 50 Health Tech, Hardware, Biotech, Manufacturing B2B Paris, France •••••••••••@eyevensys.com
LabGenius

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.

54
$25M Kindred Capital, Atomico 51 to 100 Health Tech, AI, Biotech, Deep Tech, Machine Learning, Robotics, Manufacturing B2B London, UK •••••••••••@labgeni.us
Lindus Health

Clinical trials platform.

54
$18M · Series A Valar Ventures, Seedcamp, Atomico 11 to 50 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@lindushealth.com
MinervaX

Developer of prophylactic vaccine against Group B Streptococcus.

54
$57M · Series C EQT Partners, Novo A/S, OrbiMed 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@minervax.com
Ori Biotech

Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments.

54
$30M · Series A Kindred Capital, Octopus Ventures, Amadeus Capital 1 to 10 Health Tech, Biotech, Manufacturing B2B London, UK •••••••••••@oribiotech.com
Pear Bio

Cancer treatment predictor software.

54
$14M · Series A Hoxton Ventures, Octopus Ventures, Fly Ventures 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@pearbio.com
Quell Therapeutics

Quell Therapeutics is a cell therapy company

54
$45M · Series A AlbionVC, Point72 Ventures 101 to 250 Health Tech, Edtech, Biotech, Manufacturing B2B London, UK •••••••••••@quell-tx.com
ReViral

ReViral is a biotechnology company that develops and offers antiviral therapies for patients.

54
$44M · Series C Novo A/S, Andera Partners 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@reviral.co.uk
Tropic Biosciences

Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.

54
$28M · Series B Future Planet Capital 11 to 50 Agritech, Biotech, Deep Tech, Manufacturing B2B London, UK •••••••••••@tropicbioscience.com
Farmless

Fermentation process to produce protein from animals.

54
$5M · Seed Voyager Ventures, Revent, World Fund 1 to 10 Foodtech, Biotech B2C Amsterdam, Netherlands •••••••••••@farmless.com
Hypervision Surgical

Precision software for eye surgery.

54
$8M · Seed Redalpine 1 to 10 Health Tech, Biotech London, UK •••••••••••@hypervisionsurgical.com
AAVantgarde Bio

Gene therapies for inherited retinal disorders.

54
$65M · Series A Forbion Capital Partners 1 to 10 Biotech Milan, Italy •••••••••••@aavantgardebio.com
Astraveus

Automated bioprocessing system for the production of cell and gene therapies.

54
$18M · Seed AdBio Partners 11 to 50 Biotech Paris, France •••••••••••@astraveus.com
Umedeor

Platform to automate the clinical studies process.

54
$12M · Series A Playfair, Delin Ventures, 11.2 Capital 11 to 50 Health Tech, Biotech B2B London, UK •••••••••••@umed.io
Flarin

Patent-protected anti-inflammatory painkiller.

54
$6M · Series A ITV AdVentures 1 to 10 Biotech, Pharma B2C London, UK •••••••••••@flarin.co.uk
Genomes

User-owned genomics database platform.

54
$20M · Series A GEM Digital 1 to 10 Health Tech, Biotech B2C London, UK •••••••••••@genomes.io
Gradient Denervation Technologies

Medical devices for a transvascular treatment of pulmonary hypertension.

54
$14M · Series A Sofinnova Partners, Asabys Partners 1 to 10 Health Tech, Biotech Paris, France •••••••••••@gradientdenervation.com
Laverock Therapeutics

Gene silencing platform for the creation of programmable, allogeneic cell therapies.

54
$16M · Seed Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund 1 to 10 Health Tech, Biotech London, UK •••••••••••@laverocktx.com
Floy

AI platform for radiology diagnostics.

54
$5M · Seed xdeck, 10x Founders 11 to 50 Health Tech, Biotech Munich, Germany •••••••••••@floy.com
Samabriva

Biomanufacturer of complex molecules.

54
$4M · Seed Meusinvest (Noshaq) 1 to 10 Biotech, Manufacturing Paris, France •••••••••••@samabriva.com
Hoba Therapeutics

Therapeutic protein developer for chronic neuropathic pain.

54
$24M · Series A Medical Incubator Japan, Borean Innovation, Novo A/S 1 to 10 Health Tech, Biotech Copenhagen, Denmark •••••••••••@hobatherapeutics.com
HEPHAISTOS-Pharma

Immunotherapies developer for cancer patient.

54
$2M · Seed Fournier-Majoie, Meusinvest (Noshaq), xista science ventures 1 to 10 Health Tech, Biotech Paris, France •••••••••••@hephaistos-pharma.fr
Paques Biomaterials

Polyhydroxyalkanoates (PHA) producer.

54
$15M · Seed NV NOM, Invest-NL 1 to 10 Biotech Amsterdam, Netherlands •••••••••••@paquesbiomaterials.nl
Vitestro HIRING

Autonomous blood drawing device.

51
$21M · Series A Sonder Capital, NYBC Ventures, EIC Accelerator 11 to 50 Biotech B2C Utrecht, Netherlands •••••••••••@vitestro.com
Nouscom HIRING

Viral vector-based cancer vaccines developer.

51
$82M · Series C Bpifrance, 5AM Ventures, Abingworth 1 to 10 Health Tech, Biotech B2C Basel, Switzerland •••••••••••@nouscom.com
NeurosterixJUST ADDED HIRING

Advanced allosteric modulator therapeutics developer for neurological disorders.

51
$63M · Series A Xontogeny, Perceptive Advisors, Acorn Bioventures 1 to 10 Health Tech, Biotech Geneva, Switzerland •••••••••••@neurosterix.com
Achilles Therapeutics

Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

50
$17M · Seed AlbionVC, Boxer Capital, Syncona Partners LLP 101 to 250 Health Tech, Biotech B2B London, UK •••••••••••@achillestx.com
ADmit Therapeutics

Early detection of Alzheimer's disease (AD) technology.

50
$5M · Series A EIC Accelerator, WA4STEAM, Ship2B 1 to 10 Health Tech, Biotech, Pharma B2B Barcelona, Spain •••••••••••@admit-therapeutics.com
AMSilk

Developer of bio-fabricated silk protein materials.

50
$27M · Series C Novo A/S 11 to 50 Health Tech, Biotech, Manufacturing B2B Munich, Germany •••••••••••@amsilk.com
Bactolife

Producer of gut health binding proteins.

50
$32M · Series A Bill & Melinda Gates Foundation, Novo A/S 1 to 10 Biotech, Pharma B2B Copenhagen, Denmark •••••••••••@bactolife.com
Daye

Daye is a gynecological health company that creates products and services for vaginal treatment.

50
$5M · Seed Index Ventures, Khosla Ventures, Kindred Capital 11 to 50 Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis B2C London, UK •••••••••••@yourdaye.com
EnginZyme

Bio alternative to fossil-based and energy–intensive chemical production.

50
$22M · Series B Sofinnova Partners, SEB Venture Capital, Industrifonden 51 to 100 Health Tech, Biotech B2B Stockholm, Sweden •••••••••••@enginzyme.com
Enterome

Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases.

50
$3M · Series F The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science 51 to 100 Health Tech, Biotech, Deep Tech, Pharma B2B Paris, France •••••••••••@enterome.com
Ermium Therapeutics

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases.

50
$6M · Series A Fountain Healthcare Partners 1 to 10 Health Tech, Biotech, Pharma B2B Paris, France •••••••••••@ermium.com
Hemab

Treatments for genetic bleeding disorders.

50
$135M · Series B Novo A/S, HealthCap 1 to 10 Health Tech, Biotech, Deep Tech, Pharma B2B Copenhagen, Denmark •••••••••••@hemab.com
Kuano

Quantum simulation platform for drug discovery.

50
$2M · Seed Ascension Ventures, ACF Investors 1 to 10 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@kuano.ai
Leyden Labs

Manufacturer of medicines to protect from the threat of respiratory viruses

50
$47M GV, SoftBank Group 11 to 50 Health Tech, Biotech, Deep Tech B2B Amsterdam, Netherlands •••••••••••@leydenlabs.com
Myricx Pharma

Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors.

50
$6M · Seed Sofinnova Partners 1 to 10 Health Tech, Biotech, Deep Tech, Pharma B2B London, UK •••••••••••@myricxpharma.com
nextProtein

nextProtein develops a new large-scale technology that produces a sustainable source of protein.

50
$11M · Series A Blue Oceans Partners 11 to 50 Climate Tech & Green Tech, Agritech, Foodtech, Biotech, Manufacturing B2B Paris, France •••••••••••@nextprotein.co
NorthSea Therapeutics

Innovative therapeutic drugs to treat inflammatory, metabolic and liver diseases.

50
$27M · Series A Sofinnova Partners, Novo A/S, Forbion Capital Partners 11 to 50 Health Tech, Biotech B2B Amsterdam, Netherlands •••••••••••@northseatherapeutics.com
OTHER INDUSTRIES
Other Biotech startups by location